Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hopefully Avacta AffiDX SARS-Cov-2 Lateral Flow Test will be next one to appear on this list!
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/outcome-of-the-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices
Good find, thanks. Looks like they have plenty to choose from... not necessarily British, not necessarily an AN sample type and of course not necessarily 100% sensitivity. Up to them, it’s going to be a bit awkward if this British innovation ends up going abroad. Never mind. Every extra pound per test we get from elsewhere is added on the profits...
Interesting, **** loads of competition, majority Chinese/a few German/USA but not unexpected - you'd imagine this will be the 'list' supplying the world plus us shortly
Zandcell look interesting 70m - they claim to have the largest LFT capacity globally at 95/100 SS
Surescreen and Excalibur (brain poker) the only British companies and only Surescreen with the govt contract (and Innova)
Sell all we can make still applies IMO, just get those manufacturers signed up
Again Mikey, zero completion.
Not AN
Performance measured following the onset of symptoms. ZandCell 3-5 days. I mean...
More expensive
*competition
I’m interested in the SureScreen v2... what would be the incentive to develop a second gen test?
Has anyone any data please? I’ll keep looking.
The SureScreen website is a sad joke....no info whatsoever. What on earth are they supposed to be manufacturing? Until proven otherwise I'll assume they are re-badging more Chinese crap. They probably make the packaging......that will easily fool Whitehall.
Looks like Surescreen offer three options for testing: an antigen test cassette, an immunofluorescence test, and a saliva test
https://www.surescreen.com/products/covid-19-coronavirus-antigen
Thanks.
Yes the website is deliberately ambiguous. The ‘v1’ test is not competing as it relies on symptom onset and mid turbinate design.
Zandcell are very unprofessional, as an earlier thread shows: https://www.lse.co.uk/ShareChat.asp?ShareTicker=AVCT&thread=84C482A4-1AF6-4A85-8B4C-2B6CB8216D17
Glad Avacta chose not to do business with them!
Thanks I thought the name rung a bell, the Mickey mouse outfit!
Worth baring in mind that there was no 'validated test' as at the 15th March and still nothing from ODX, so the government clearly going British
In reality, manufacturing capacity will drive the sovereign test choice. That’s what I’m most interested to hear about tomorrow. Alongside licensing. These forecasts and opp’s should be a welcome surprise.
Surescreen v2 could just be surescreen v1 with different instructions.
It’s all a bit weird anyway, a bizarre vanity parade as all the foreign/unsuitable tests get wheeled through PD to be accepted on to the DPS where they don’t fulfil the govt’s aim of a sovereign AN test and get kicked back out. The one test that could meet the requirements can’t make it through PD due to the freezer. Nothing would surprise me, could be a direct award, could be a change in requirements to allow us in or could be that they’ve already dug their heels in and that’s why PresAl has taken us down a fully independent route - that ultimately could be way more lucrative
Have not seen any contract for ABDX for sovereign test only the other two. You sure they are involved?
PL - Good point.
Agree the whole process is a farce. Excalibur... it’s a list of tests I’d rather not be included on. AS has made it clear enough that he’d like it to be credible. The work that’s gone into it’s design and validation is super important. And in time, I think we’ll appreciate it even more.
Found this while research the SureScreen v2 test: https://www.bmj.com/content/372/bmj.n423
Decent read, nothing to report as such. But does indicate that the v2 test was around in August last year.
Anyway. It’s all academic now. We have the unicorn and monetising it through manufacture and third party licensing is the success I’m sure we’ll get more on tomorrow.
Was that the correct link? That was about a pointless antibody test evaluation
Sorry - wrong link!
This was it: https://www.medrxiv.org/content/10.1101/2020.12.01.20237784v2.full-text
Assessment of the Innova LFT. The study was interesting. Very sad how you can grow to find studies like this of interest :)